Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Rose AAN, Biondini M, Curiel R, Siegel PM.

Pharmacol Ther. 2017 Nov;179:127-141. doi: 10.1016/j.pharmthera.2017.05.010. Epub 2017 May 22. Review.

PMID:
28546082
2.

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM.

Clin Cancer Res. 2016 Dec 15;22(24):6088-6098. Epub 2016 Aug 11.

3.

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R.

Pediatr Blood Cancer. 2016 Jan;63(1):32-8. doi: 10.1002/pbc.25688. Epub 2015 Aug 25.

PMID:
26305408
4.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
5.

Antibody-drug conjugate for advanced melanoma?

Sharma SP.

Lancet Oncol. 2014 Nov;15(12):e534. Epub 2014 Oct 10. No abstract available.

PMID:
25602109
6.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.

J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.

PMID:
25267761
7.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P.

J Clin Oncol. 2014 Nov 10;32(32):3659-66. doi: 10.1200/JCO.2013.54.8115. Epub 2014 Sep 29.

8.

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. doi: 10.1002/pbc.25099. Epub 2014 Jun 9.

9.

Novel data in metastatic breast cancer.

Vahdat LT.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):13-5. No abstract available.

PMID:
24637556
10.

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).

Vaklavas C, Forero A.

BioDrugs. 2014 Jun;28(3):253-63. doi: 10.1007/s40259-014-0085-2. Review.

PMID:
24496926
11.

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.

Keir CH, Vahdat LT.

Expert Opin Biol Ther. 2012 Feb;12(2):259-63. doi: 10.1517/14712598.2012.642357. Epub 2012 Jan 9. Review.

PMID:
22229970
12.

Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.

Zhou LT, Liu FY, Li Y, Peng YM, Liu YH, Li J.

Neoplasma. 2012;59(1):1-5. doi: 10.4149/neo_2012_001. Review.

PMID:
22017590
13.

GPNMB expression in uveal melanoma: a potential for targeted therapy.

Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P.

Melanoma Res. 2010 Jun;20(3):184-90. doi: 10.1097/CMR.0b013e3283364a08.

PMID:
20375921
14.

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM.

Clin Cancer Res. 2010 Apr 1;16(7):2147-56. doi: 10.1158/1078-0432.CCR-09-1611. Epub 2010 Mar 9.

Supplemental Content

Loading ...
Support Center